LONP1 and cancer: Emerging evidence suggests that inhibiting LonP1 or other quality control proteins in mitochondria (54, 55) and endoplasmic reticulum (56) of cancer cells or immunosuppressor cells (57) is a potential strategy for disabling oncogenic progression.